Bevacizumab in Japanese patients with malignant glioma: from basic research to clinical trial

Shingo Takano; Eiichi Ishikawa; Kei Nakai; Masahide Matsuda; Tomohiko Masumoto; Tetsuya Yamamoto; Akira Matsumura
September 2014
OncoTargets & Therapy;2014, Vol. 7, p1551
Academic Journal
An antiangiogenic approach is especially suitable for the treatment of malignant gliomas. Recently, two large clinical trials in newly diagnosed glioblastoma (the Avastin in Glioblastoma study and Radiation Therapy Oncology Group 0825 study) showed a 3- to 4-month prolongation of progression-free survival (PFS) with bevacizumab, but no significant effect on overall survival (OS). Japan is the first, and so far only, country to approve the use of bevacizumab in newly diagnosed glioblastoma in combination with radiotherapy and temozolomide chemotherapy. The drug is also approved for use as monotherapy for recurrent glioblastoma and certain other types of high-grade glioma after previous therapy. The effectiveness of bevacizumab on Japanese malignant glioma patients was reviewed. The Phase II clinical trial demonstrated that the PFS with bevacizumab alone was 34% at 6 months and 3.3 months at median for 32 patients with recurrent malignant gliomas. In the Avastin in Glioblastoma study, 44 Japanese patients were registered from Japan. PFS and OS for bevacizumab combined with standard temozolomide and radiotherapy were 12.2 months and 29.2 months at median, respectively, for the patients with newly diagnosed glioblastoma. PFS and OS tended to be longer for those treated with bevacizumab than for those not treated with the drug. In addition, biomarkers of bevacizumab effectiveness were investigated in Japanese patients. Vascular endothelial growth factor concentration, matrix metalloproteinase 9 activities in urine, and apparent diffusion coefficient values on magnetic resonance imaging may be biomarkers that predict patient prognosis. Finally, novel experiments for vascular endothelial growth factor antibody action were described; these include the induction of glioma cell apoptosis, an antibody treatment failure model, and a study of the synergistic effect with chemotherapeutic agents.


Related Articles

  • Salvage therapy with single agent bendamustine for recurrent glioblastoma. Chamberlain, Marc; Johnston, Sandra // Journal of Neuro-Oncology;Dec2011, Vol. 105 Issue 3, p523 

    The treatment of recurrent glioblastoma (GBM) remains challenging notwithstanding the recent approval of bevacizumab for this indication. Bendamustine has a bifunctional mechanism of action including alkylation, penetrates the CNS and does not show cross resistance to other alkylator...

  • Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. VAN LINDE, MYRA E.; VERHOEFF, JOOST J. C.; RICHEL, DIRK J.; VAN FURTH, WOUTER R.; REIJNEVELD, JAAP C.; VERHEUL, HENK M. W.; STALPERS, LUKAS J. A. // Oncologist;Feb2015, Vol. 20 Issue 2, p107 

    BACKGROUND: Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent. Bevacizumab (BV) may increase...

  • Bevacizumab for Glioblastoma--A Promising Drug or Not? Motoo Nagane; Ryo Nishikawa // Cancers;Dec2013, Vol. 5 Issue 4, p1456 

    Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS's were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence,...

  • Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis. Salloum, Ralph; DeWire, Mariko; Lane, Adam; Goldman, Stewart; Hummel, Trent; Chow, Lionel; Miles, Lili; Sutton, Mary; Stevenson, Charles; Fouladi, Maryam; Leach, James // Journal of Neuro-Oncology;Feb2015, Vol. 121 Issue 3, p591 

    There is a paucity of data regarding patterns of progression in children with high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) treated with bevacizumab (BVZ) at diagnosis. We performed a retrospective study of 20 children with HGG or DIPG who received BVZ-based therapy at...

  • Ovarian Cancer Drug Slows Disease Progression.  // Healthy Years;Mar2012, Vol. 9 Issue 3, p4 

    The article the findings of a study on an ovarian cancer drug that can slow disease progression. The study included women diagnosed with Stage III or IV ovarian cancer who had undergone surgery. It divided the women into three treatment groups, one that received bevacizumab for cycles 2 through...

  • Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer. Pujade-Lauraine, Eric // Journal of Gynecologic Oncology;Jul2013, Vol. 24 Issue 3, p209 

    The author reflects on the effectiveness of oral metronomic cyclophosphamide (OMC) and bevacizumab against recurrent ovarian cancer. He says that bevacizumab has response rate ranging from 16%-21% if used as a single-agent drug, in which randomized trials have shown improved progression-free...

  • Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. PETERS, KATHERINE B.; LOU, EMIL; DESJARDINS, ANNICK; REARDON, DAVID A.; LIPP, ERIC S.; MILLER, ELIZABETH; HERNDON II, JAMES E.; MCSHERRY, FRANCES; FRIEDMAN, HENRY S.; VREDENBURGH, JAMES J. // Oncologist;2015, Vol. 20 Issue 7, p727 

    Background. Extent of resection remains a key prognostic factor in glioblastoma (GBM), with gross total resection providing a better prognosis than biopsy or subtotal resection. We conducted a phase II trial of upfront therapy with bevacizumab (BV), irinotecan (CPT-11), and temozolomide (TMZ)...


    No abstract available.

  • Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report. Bota, Daniela A.; Alexandru-Abrams, Daniela; Pretto, Chrystel; Hofman, Florence M.; Chen, Thomas C.; Fu, Beverly; Carrillo, Jose A.; Schijns, Virgil E. J. C.; Stathopoulos, Apostolos // Permanente Journal;Spring2015, Vol. 19 Issue 2, p41 

    Objectives: Glioblastoma multiforme (GBM) is a highly aggressive tumor, which recurs despite resection, focal beam radiation, and temozolomide chemotherapy. At recurrence, the only second-line treatment approved by the US Food and Drug Administration is bevacizumab (Avastin). To date, no single...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics